Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-5. (canceled)

6. (previously presented) A method for treating prostate cancer in an individual suffering from prostate cancer, comprising the steps of initiating androgen-withdrawal to induce apoptotic cell death of prostatic tumor cells in the individual, and administering to the individual a composition effective to inhibit expression of TRPM-2 by the tumor cells, thereby delaying the progression of prostatic tumor cells to an androgen-independent state in an individual, wherein the composition effective to inhibit expression of TRPM-2 is an antisense oligonucleotide.

7. (canceled)

8. (previously presented) The method of claim 6, wherein the antisense oligonucleotide is complementary to a region of TRPM-2 mRNA including the translation initiation or termination site.

9. (currently amended) The method of claim 6 ~~8~~, wherein the antisense oligonucleotide consists of ~~has~~ the sequence given by SEQ ID No. 4.

10. (currently amended) The method of claim 6 ~~8~~, wherein the antisense oligonucleotide consists of ~~has~~ the sequence given by SEQ ID No. 5.

11. (currently amended) The method of claim 6 ~~8~~, wherein the antisense oligonucleotide consists of ~~has~~ the sequence given by SEQ ID No. 12.

12. (previously presented)The method of claim 8, further comprising the step of administering to the individual a chemotherapy agent.

13. (previously presented)The method of claim 12, wherein the chemotherapy agent is a taxane or mitoxanthrone.

14. (previously presented)The method of claim 8, further comprising the step of administering to the individual a second antisense oligodeoxynucleotide which inhibits expression of an anti-apoptotic protein other than TRPM-2.

15. (original) The method of claim 14, wherein the second antisense oligodeoxynucleotide is antisense Bcl-2 oligodeoxynucleotide.

16. (original) The method of claim 14, further comprising the step of administering to the individual a chemotherapy agent.

17. (original) The method of claims 16, wherein the chemotherapy agent is a taxane or mitoxanthrone.

18-28. (canceled)

29. (previously presented) The method of claim 9, further comprising the step of administering to the individual a chemotherapy agent.

30. (previously presented)The method of claim 9, further comprising the step of administering to the individual a second antisense oligodeoxynucleotide which inhibits expression of an anti-apoptotic protein other than TRPM-2.

31. (previously presented) The method of claim 10, further comprising the step of administering to the individual a chemotherapy agent.

32. (previously presented) The method of claim 10, further comprising the step of administering to the individual a second antisense oligodeoxynucleotide which inhibits expression of an anti-apoptotic protein other than TRPM-2.

33. (previously presented) The method of claim 11, further comprising the step of administering to the individual a chemotherapy agent.

34. (previously presented) The method of claim 11, further comprising the step of administering to the individual a second antisense oligodeoxynucleotide which inhibits expression of an anti-apoptotic protein other than TRPM-2.

35. (currently amended) The method of claim 6 ~~8~~, wherein the antisense oligonucleotide is complementary to a region of the TRPM-2 mRNA that is complementary to SEQ ID NO: 4.

36. (currently amended) The method of claim 6 8, wherein the antisense oligonucleotide is complementary to a region of the TRPM-2 mRNA that is complementary to SEQ ID NO: 5.

37. (currently amended) The method of claim 6 8, wherein the antisense oligonucleotide is complementary to a region of the TRPM-2 mRNA that is complementary to SEQ ID NO: 12.

38. (previously presented) A method for treating prostate cancer in an individual suffering from prostate cancer, comprising the steps of administering to the individual a composition effective to inhibit expression of TRPM-2 by the tumor cells, and administering to the individual

a chemotherapy agent, wherein the composition effective to inhibit expression of TRPM-2 is an antisense oligonucleotide.

39. (previously presented) The method of claim 38, wherein the chemotherapy agent is a taxane or mitoxanthrone.

40 (new) The method of claim 38, wherein the antisense oligonucleotide is complementary to a region of TRPM-2 mRNA including the translation initiation or termination site.

41. (new) The method of claim 38, wherein the antisense oligonucleotide comprises the sequence given by SEQ ID No. 4.

42. (new) The method of claim 38, wherein the antisense oligonucleotide comprises the sequence given by SEQ ID No. 5.

43. (new) The method of claim 38, wherein the antisense oligonucleotide comprsies the sequence given by SEQ ID No. 12.